Patient description: The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed: IPSS score : 15 Post-void residual: 70 mL Prostate volume (TRUS): 60 mL Prostate-specific antigen (PSA) level: 3.2 ng/mL 10 mL/sec of maximum flow rate when urine volume was 130 mL He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: Hgb: 13.5 g/dl WBC: 135000 /mm3 Plt: 350000 /ml PT: 11 second PTT: 35 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Benign Prostatic Hyperplasia All subjects are required to meet the following in order to be considered eligible for participation in this trial: 1. ≥ 45 years of age 2. Baseline IPSS score > 13, and a baseline Quality of Life (QoL) question score > 3 3. Prostate volume 25 cc by Trans Rectal Ultrasound (TRUS), measured within past 90 days and prostatic urethral length between 2.5-4.5 cm. 4. Failed or intolerant to medication regimen for the treatment of LUTS  Subjects will be excluded from participating in this trial if they meet any of the following 1. Obstructive intravesical median prostatic lobe or high bladder neck 2. Urethral stricture, meatal stenosis, or bladder neck obstruction either current, or recurrent requiring 2 or more dilatations 3. Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer 4. Elevated risk of prostate cancer 5. Post-void residual volume (PVR) > 250 ml 6. Peak urinary flow rate > 12 ml/second, with ≥ 125 ml voided volume at baseline 7. History of chronic urinary retention 8. History of neurogenic bladder 9. Compromised renal function (e.g., serum creatinine > 1.8 mg/dl) due to bladder obstruction 10. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test) 11. Concomitant bladder stones 12. Confirmed or suspected bladder cancer 13. Previous pelvic irradiation or radical pelvic surgery 14. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate 15. Chronic prostatitis, or recurring prostatitis within the past 12 months 16. Serious concurrent medical conditions such as uncontrolled diabetes 17. Known allergy to nickel 18. Life expectancy less than 24 months 19. Use of concomitant medications (e.g., anticholinergics, antispasmodics or antidepressants) affecting bladder function 20. Patients taking coumadin 3 days or less prior to procedure and have INR value > 1.5 on day of procedure. ASA and clopidogrel must be ceased 7 days prior to the procedure 21. 5 alpha reductase inhibitors within 6 months of pre-treatment evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued for entrance into or throughout the study) 22. alpha blockers within 2 weeks of pre-treatment evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued for entrance into or throughout the study) 23. Future fertility concerns 24. Any severe illness that might prevent study completion or would confound study results